Gaita F, Giustetto C, Libero L, Riccardi R, Bocchiardo M, Scaglione M, Lamberti F, Richiardi E, Brusca A, Massa R
Divisione di Cardiologia, Ospedale Civile, Asti.
G Ital Cardiol. 1995 Jun;25(6):695-706.
Idiopathic verapamil-responsive left ventricular tachycardia (IVRLVT) is a rare, well known form of ventricular tachycardia. Issues concerning long-term prognosis, drug prophylaxis and non-pharmacological therapy are rarely reported in the literature. We report the long-term follow-up, the efficacy of various drugs in the prophylaxis and the role of catheter ablation in a large group of patients with IVRLVT.
This retrospective study involves 37 patients with a mean age of 28.3 +/- 14.8 years at first IVRLVT episode. The tachycardia morphology was typically with a right bundle-branch block configuration in all cases, with left axis deviation in 33 and right axis deviation in 5 (one patient had the 2 morphologies). Four patients had a mitral valve prolapse; the remaining 33 patients had neither clinical nor echocardiographic signs of heart disease. Only sporadic ventricular extrasystoles were detected at Holter monitoring in 73% of cases; 30% of patients had positive criteria for the presence of late potentials at signal averaged ECG. During electrophysiologic study, the tachycardia could be easily induced in 91% of patients. Mean follow-up is 7.3 +/- 4.7 years; all patients are alive at the end of follow-up. A mean of 2.3 +/- 1.2 drugs was prescribed in 35 patients (94.6%); betablockers were effective in 66% of the cases, verapamil in 20%, class I drugs in 22%, class III drugs in 15%. Both the 2 patients, who never received prophylaxis, and the 4 who stopped medication, utilize verapamil in case of recurrences. Eight patients were submitted to catheter ablation, with DC shock the first 2 patients, with RF energy from the third on; all but one (with DC shock) were successfully cured.
Long-term follow-up confirmed the good prognosis of this form of ventricular tachycardia; a new insight that has been addressed about prophylaxis is the high efficacy of betablockers in preventing relapse and the poor efficacy of verapamil per os in chronic prophylaxis. Radiofrequency catheter ablation is effective and safe, using the earliest ventricular potential and the pace-mapping reproducing the same morphology of the tachycardia in all the 12 leads as a marker to identify the site of RF application, and may be proposed to all patients suffering from frequent episodes of IVRLVT.
特发性维拉帕米敏感性左室性心动过速(IVRLVT)是一种罕见但广为人知的室性心动过速形式。关于其长期预后、药物预防及非药物治疗的问题在文献中鲜有报道。我们报告了一大组IVRLVT患者的长期随访情况、各种药物预防的疗效以及导管消融的作用。
这项回顾性研究纳入了37例患者,首次发生IVRLVT时的平均年龄为28.3±14.8岁。所有病例的心动过速形态典型地呈右束支传导阻滞图形,33例为电轴左偏,5例为电轴右偏(1例患者有两种图形)。4例患者有二尖瓣脱垂;其余33例患者无心脏病的临床及超声心动图征象。动态心电图监测发现73%的病例仅偶发室性期前收缩;30%的患者信号平均心电图有晚电位阳性标准。在电生理检查中,91%的患者心动过速可被轻易诱发。平均随访时间为7.3±4.7年;随访结束时所有患者均存活。35例患者(94.6%)平均使用2.3±1.2种药物;β受体阻滞剂在66%的病例中有效,维拉帕米在20%,I类药物在22%,III类药物在15%。从未接受预防治疗的2例患者以及停止用药的4例患者在复发时均使用维拉帕米。8例患者接受了导管消融,前2例患者使用直流电休克,从第3例开始使用射频能量;除1例(接受直流电休克的患者)外均成功治愈。
长期随访证实了这种室性心动过速形式预后良好;关于预防方面新的认识是β受体阻滞剂预防复发的疗效高,而口服维拉帕米在慢性预防中的疗效差。射频导管消融有效且安全,以最早的心室电位及在12导联中重现心动过速相同形态的起搏标测作为确定射频应用部位的标志,可推荐给所有IVRLVT发作频繁的患者。